This site is intended for health professionals only!

Altacor growth ‘to accelerate’

Esperante, the private, Netherlands-based life science investment company, has announced it has completed the acquisition of Altacor Limited, a specialty ophthalmology company.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.

Esperante, the private, Netherlands-based life science investment company, has announced it has completed the acquisition of Altacor Limited, a specialty ophthalmology company.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company, PolyPeptide Laboratories, a global peptide bulk drug actives producer and Euro-Diagnostica, a European-based immunology in vitro diagnostics business.
Under Esperante’s stewardship Altacor will continue to operate as a specialty ophthalmology company and expects to develop its revenues and market presence significantly by:
• Expanding its commercial business and specifically the market share of its existing portfolio of Clinitas® products for dry eye, the blepharitis range (Blephakit®) and ocular supplements (Eyebar®) extending its geographic sales reach;
• Adding to the marketing portfolio by the acquisition and in-licensing of novel ophthalmic therapies and surgical devices;
• Increasing its marketing portfolio by advancing its current pipeline, which is focused on fast to market, repositioned and orphan products; and
• Leveraging opportunities within Esperante and its sister companies.
Dean Slagel, Managing Director of Esperante, said, “Esperante has been a minority investor in Altacor for the past 5 years and we are now very excited to be acquiring the entire business to propel Altacor’s promising product and pipeline product portfolio towards an ever more successful and profitable level. We look forward to achieving these objectives in close collaboration with Altacor’s well-proven management team.”
Dr Fran Crawford, CEO of Altacor, added, “We are extremely pleased that Altacor has been acquired by Esperante and that it plans to pursue and expand the company’s existing strategy within a holding group that has a successful track record in building European businesses. I am also delighted that our staff will all remain in position and will continue to drive product sales and pipeline development in the company’s chosen markets.”
Altacor were advised in this transaction by Longcross Advisers LLP. Financial terms were not disclosed.



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: